Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
H5429 is a Rhode Island insurance bill aimed at lowering prescription drug costs by increasing transparency and accountability for pharmacy benefit managers (PBMs) and related health insurance administrators. The bill expressly states its intent to protect Rhode Islanders from high drug prices and would require PBMs to operate under stricter reporting, pricing, and conduct rules. It also expands the Health Insurance Commissioner’s oversight role over PBMs and health insurers, including enforcement authority and the ability to impose civil fines for violations.
The bill would amend Rhode Island law to treat PBMs as third-party administrators under the state’s insurance code and require annual reporting of financial arrangements, affiliate relationships, and other information to the Department of Business Regulation as public records. It would prohibit spread pricing, require pass-through pricing, bar discriminatory treatment of non-affiliated pharmacies, and restrict utilization management practices such as prior authorization, step therapy, and non-medical drug switching when they delay or prevent medically necessary care. It also directs that enrollee benefits reflect discounts and rebates provided by drug manufacturers and requires PBMs to provide documents needed for enforcement.
Beyond PBM regulation, the bill adds to the Health Insurance Commissioner’s duties by requiring public meetings, reporting, and analysis on a wide range of health insurance issues, including administrative costs, market competition, provider reimbursement, prior authorization, continuity of care, behavioral health parity, hospital payment variation, and social and human service program rates. It also creates or continues multiple workgroups and reporting obligations intended to streamline healthcare administration and improve transparency in insurer-provider interactions. In practical terms, the bill would broaden state oversight of commercial health insurance operations and create new compliance obligations for insurers, PBMs, and administrators.
The overall sentiment reflected in the bill text and caption is strongly supportive of consumer protection and cost control, with a focus on transparency and market accountability. Because there were no committee transcripts or recorded votes provided, there is no documented floor or committee debate to indicate broader legislative support or opposition. The bill’s framing suggests a policy goal of reducing prescription drug costs and improving access to care, rather than a partisan or procedural dispute.
The main points of contention likely center on the bill’s restrictions on PBM business practices and the scope of state regulatory authority. PBMs and affiliated insurers may object to bans on spread pricing, mandatory pass-through pricing, disclosure of contractual and affiliate information, and limits on utilization management tools such as prior authorization and step therapy. Health plans and administrators may also view the bill’s reporting, public disclosure, and enforcement provisions as administratively burdensome, while supporters would likely argue that these measures are necessary to curb opaque pricing practices and protect patients and pharmacies.
The bill would amend Rhode Island’s insurance statutes, especially the chapters governing third-party administrators, pharmacy freedom of choice, and health insurance oversight. It would place PBMs squarely under the state’s third-party administrator framework, require new public reporting and disclosure obligations, and authorize the Health Insurance Commissioner to promulgate rules, hire staff or contractors, and enforce PBM compliance with civil penalties. It would also expand the commissioner’s duties across multiple health policy areas, increasing state oversight of insurers, PBMs, provider practices, and healthcare administrative processes.
The bill’s overall sentiment is consumer-oriented and reform-minded, with a clear emphasis on lowering prescription drug costs, increasing transparency, and strengthening state oversight of insurers and PBMs. The available materials do not include committee testimony or votes, so there is no direct record of support or opposition from legislators or stakeholders. Based on the bill text alone, the measure appears designed to appeal to patients, pharmacies, and consumer advocates concerned about drug affordability and insurer practices.
The most likely areas of contention are the bill’s restrictions on PBM pricing models and utilization management, as well as its broad disclosure and enforcement requirements. PBMs and affiliated insurers may resist the prohibition on spread pricing, the requirement to use pass-through pricing, and the limits on prior authorization, step therapy, and non-medical drug switching. They may also object to mandatory public disclosure of financial arrangements and affiliate structures, while supporters would likely argue these provisions are needed to prevent hidden markups, improve competition, and ensure that savings reach enrollees.